AU2002224322A1 - Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease - Google Patents

Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease

Info

Publication number
AU2002224322A1
AU2002224322A1 AU2002224322A AU2432202A AU2002224322A1 AU 2002224322 A1 AU2002224322 A1 AU 2002224322A1 AU 2002224322 A AU2002224322 A AU 2002224322A AU 2432202 A AU2432202 A AU 2432202A AU 2002224322 A1 AU2002224322 A1 AU 2002224322A1
Authority
AU
Australia
Prior art keywords
peptiderelease
dipeptide
amyloid
lactam
inhibiting beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224322A
Inventor
Thomas Mitchell Koenig
David Mitchell
Jeffrey Scott Nissen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2002224322A1 publication Critical patent/AU2002224322A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides crystalline (N)-((S)-2-hydroxy-3-methyl-butyryl-1-(L-alaninyl)-(S)-1-amino-3-methyl-4,5,6,7-tetrahydro-2H-3-benzazepin-2-one anhydrate, compositions thereof, and methods for using the same, processes for making the same, and processes for making intermediate thereof.
AU2002224322A 2000-11-17 2001-11-02 Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease Abandoned AU2002224322A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24965500P 2000-11-17 2000-11-17
US60/249,655 2000-11-17
PCT/US2001/027796 WO2002040508A2 (en) 2000-11-17 2001-11-02 Lactam dipeptide and its use in inhibiting beta-amyloid peptide release

Publications (1)

Publication Number Publication Date
AU2002224322A1 true AU2002224322A1 (en) 2002-05-27

Family

ID=22944432

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224322A Abandoned AU2002224322A1 (en) 2000-11-17 2001-11-02 Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease

Country Status (8)

Country Link
EP (1) EP1345955B1 (en)
JP (1) JP2005538031A (en)
AT (1) ATE405577T1 (en)
AU (1) AU2002224322A1 (en)
CA (1) CA2425558C (en)
DE (1) DE60135489D1 (en)
ES (1) ES2311561T3 (en)
WO (1) WO2002040508A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
US8828684B2 (en) 2004-07-27 2014-09-09 The Regents Of The University Of California Genetically modified host cells and use of same for producing isoprenoid compounds
KR20070116865A (en) 2005-04-08 2007-12-11 다이이찌 산쿄 가부시키가이샤 Pyridylmethylsulfone derivative
US8258302B2 (en) 2006-01-31 2012-09-04 Api Corporation Method for producing benzazepinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
CN102690231B (en) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 Method for synthesizing potential drug of Semagacestat for treating Alzheimer disease

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition
EA002100B1 (en) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHOD FOR INHIBITING beta-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESISBY USE OF SUCH COMPOUNDS
PL345885A1 (en) * 1998-08-07 2002-01-14 Smithkline Beecham Plc Process for the preparation of a non-crystalline anhydrate form of paroxetine hydrochloride

Also Published As

Publication number Publication date
JP2005538031A (en) 2005-12-15
EP1345955A2 (en) 2003-09-24
CA2425558A1 (en) 2002-05-23
EP1345955B1 (en) 2008-08-20
CA2425558C (en) 2012-01-03
WO2002040508A2 (en) 2002-05-23
WO2002040508A3 (en) 2003-03-27
ATE405577T1 (en) 2008-09-15
DE60135489D1 (en) 2008-10-02
ES2311561T3 (en) 2009-02-16

Similar Documents

Publication Publication Date Title
WO2002047671A3 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
YU15299A (en) Pharmaceutical compositions
WO2001079461A3 (en) Polypeptides having haloperoxidase activity
AU4048299A (en) Phenoxylpropanolamines, method for the production thereof and pharmaceutical compositions containing the same
BG101194A (en) New heteroaryl oxazolidinons
ZA989560B (en) Compositions containing an Ó 1,2-fucose linkage and uses thereof.
AU2001235737A1 (en) Novel 1,3-dihydro-2h-indol-2-one, preparation method and pharmaceutical compositions containing same
AU4314199A (en) Compounds, compositions and methods for treating erectile dysfunction
AU1278100A (en) 2-acylamino-2-deoxy-glucono-1,5-lactones, method for obtaining same, compositions comprising them and uses
WO2002040451A3 (en) Lactam compound
ZA99733B (en) Ophthalmic composition.
AU2001275085A1 (en) Methods, compounds and compositions for treating gout
AU2002224322A1 (en) Lactam dipeptide and its use in inhibiting beta-amyloid peptiderelease
ZA97188B (en) Disinfecting compositions and processes for disinfecting surfaces.
AU2253100A (en) Compositions obtained from (mangifera indica l.)
AU2001259037A1 (en) Hydrogenated block copolymer compositions
AU2001288736A1 (en) Method and composition for enhancing vision
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
ZA979642B (en) Heterocyclic compounds, compositions and uses.
ZA979643B (en) Heterocyclic compounds, compositions and uses.
ZA979649B (en) Heterocyclic compounds, compositions and uses.
AU1730797A (en) 3-substituted-4-oxa-1-azabicyclo{3,2,0}heptan-7-one as cysteine protease inhibitors
AU7655600A (en) 1,4-dioxacycloalkane-2-one and 1,4-dioxacycloalkene-2-one
MXPA02007005A (en) PSEUDOPOLYMORPH OF ()CIS2(2CHLOROPHENYL)5, 7DIHYDROXY8[4R(3SHYDROXY1METHYL)PIPERIDINYL]4Hminu s;1BENZOPYRAN4ONE.
ZA979646B (en) Heterocyclic compounds, compositions and uses.